Role of MDCT in Assessment of Pleuropneumonic Changes After Breast Cancer Radiotherapy.

Abstract

Back ground: Breast cancer radiotherapy plays an important role and can reduce local and regional recurrence, however may be complicated by radiation pneumonitis, the early stage occurs one to three months after treatment characterized mainly by ground glass opacities and consolidate-ion related to radiation portal. The late phase develops six months after the completion of radiation therapy and can progress for as long as two years manifested by atelectactic bands bronchiectasis and lung fibrosis. MDCT has an important role in assessment of lung and pleural changes with grading of these changes. Aim of the work:To show the role of MDCT in assessment of pleuropneumonic changes after breast cancer radiotherapy.